Deepak Nitrite Ltd

- There is no immediate pressure on cash flow for the INR 5,000 crore polycarbonate resin manufacturing project, as Deepak Nitrite has a liquid surplus of around INR 800 crore. - Payments to the technology partner Trinseo are being made in a phased manner. - The company has available credit limits ("doable limits") to support funding if needed. - Deepak Nitrite will communicate detailed funding plans through debt and equity after evaluating various options in due course. - Overall, fundraising plans are balanced and contingent upon project engineering completion; no urgent or definitive debt/equity raise has been announced so far.

- INR 5,000 crore approved for manufacturing polycarbonate resins, including greenfield infrastructure and capital expenditure; commissioning expected around end FY27 and ramp-up by 2028-29. - INR 2,000 crore capex for backward and forward integration projects (nitric acid, phenol, BPA) expected to start commissioning from H2 FY26. - Total capex plan of approx. INR 14,000 crore till 2027; around INR 7,000 crore committed, balance for Phase 2 expansions. - Investment in polycarbonate compounding via INR 34.5 crore in OXOC Chemical Limited for forward integration. - New R&D center near Vadodara with approx. INR 115 crore capex (66% utilized), supporting specialty chemicals and polycarbonate compounding. - Projects including MIBK/MIBC, acetophenone, nitric acid, cumene hydroperoxide, hydrogenation blocks under commissioning in next 6-12 months. - Funding from a balanced mix of debt and equity; liquid surplus (~INR 800 crore) and available credit lines support investment plans.

- Anticipated demand uptick in legacy European customers in latter half of 2024 due to end of China's destocking, improving product pricing. - Expecting margin expansion and volume recovery in Advanced Intermediates from Q4 FY25 onwards. - Agrochemical segment sales impacted in earlier quarters but expected to recover strongly in H2 FY25 and CY25. - Phenolics segment showing robust growth with revenues up 29% YoY in Q2 FY25, sustained by high utilization and favorable domestic consumption. - Overall consolidated revenues grew 14% YoY in Q2 and 18% in H1 FY25, driven by phenolics and expanded capacity. - Expansion projects (e.g., nitric acid, polycarbonate, BPA, phenol) to commission from H2 FY25 through 2028, enabling volume growth and integrated business benefits. - Focus on new products and markets, including strong R&D efforts, to broaden customer base and increase volumes. - CY25 expected to be more positive with normalized global market conditions and stable growth trajectory.

- The company anticipates margin expansion starting Q4 FY25, driven by new product launches with margin-protection clauses via raw material cost pass-throughs. - Phenolics segment shows strong growth with 29% revenue increase YoY and 15% EBIT margin, supporting profitability. - Advanced Intermediates segment faces current pricing pressures but expects meaningful improvement from Q4 FY25 onwards. - EBITDA for H1 FY25 grew 15% YoY to INR 647 crore with margins at 15%, indicating solid operational performance. - Integrated new projects (BPA, phenol, polycarbonate) expected to enhance margins and resilience, with benefits ramping up from H2 FY26 onwards. - INR 5,000 crore polycarbonate project (starting revenue flow from 2028) is part of a broader capex plan (~INR 14,000 crore) spread over next 3 years, aiming for long-term IRR and payback but detailed figures pending further project announcements. - Company confident about recovery in agrochemical demand and normalization in CY25 supporting growth.

The transcript provided from Deepak Nitrite Limited's Q2 & H1 FY25 earnings call does not explicitly mention the current or expected order book or pending orders. However, relevant points regarding demand and outlook include: - Anticipated demand uptick from legacy European customers in H2 FY25, aligning with end of China's destocking. - Recovery seen in various product segments with expected margin expansions from Q4 FY25 onwards. - Agrochemical segment faced volume revisions but expected significant improvement in volumes starting Q4 FY25. - Integration of backward and forward capacities (nitric acid, MIBK, MIBC, etc.) expected to enhance margins and ROCE starting H2 FY26. - Projects progressing well with commissioning expected in next 6-12 months to contribute to growth. No direct order book size or pending orders figures were disclosed.